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Stereodifferentiation in the fluorescence of naproxen-arginine 
salts in the solid state 
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Abstract— Three stereoisomeric salts of naproxen (NPX) with arginine (Arg), namely (S)-NPX/(S)-Arg, (R)-NPX/(S)-Arg and (S)-
NPX/(R)-Arg, have been prepared, and their fluorescence spectra recorded in solution and in the solid state. While the emission properties 
in solution did not show significant differences, with λmax = 355 nm, τF (MeOH) ca 11.5 ns and τF (H2O) ca 9 ns (as NPX/Na), the (R)-
NPX/(S)-Arg and (S)-NPX/(R)-Arg solid salts displayed red-shifted fluorescence spectra with maxima at 375 nm and τF = 1.1 ns. By 
contrast, the behaviour of solid (S)-NPX/(S)-Arg was similar to that of NPX/Na, with λmax = 355 nm and τF ca 5.5 ns. These results are 
explained based on the X-ray crystal structures and attributed to formation of NPX excimers emitting at longer wavelengths. Accordingly, 
such excimer emission was also observed in the fluorescence spectrum of a model NPX dyad in solution. 
© 2018 Elsevier Science. All rights reserved 
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1. Introduction 
Arylpropionic acids such as ibuprofen, naproxen, 
flurbiprofen and ketoprofen belong to the family of non-
steroidal anti-inflammatory drugs (NSAIDs), widely used 
as therapeutic agents for the treatment of a broad spectrum 
of pathophysiological conditions. These include very 
common processes as fever, headaches and pain caused by 
degenerative diseases, as well as osteo and rheumatoid 
arthritis.1 
The activity of NSAIDs is associated with inhibition of 
the cyclooxygenase synthesis of the enzyme prostaglandin 
endoperoxide synthase (PGHS).2,3 This enzyme, also 
known as cyclooxygenase or COX, is a membrane protein 
that catalyzes in two steps the oxidation of arachidonic acid 
into hydroxy endoperoxide (PGH2), which is the precursor 
of physiologically important agents as thromboxanes, 
prostaglandins and prostacyclins. Two isoforms of COX 
are known, namely COX-1 and COX-2. The amino acid 
sequences of three COX-1 and four COX-2 enzymes 
obtained from different sources are known.4 The residues at 
the cyclooxygenase binding site identified as being directly 
involved in the ligand-enzyme interaction include Arg 
(making a salt bridge) and Tyr (through hydrogen bonding) 
5 This has been confirmed in the case of several COX-1 and 
COX-2 complexed with NSAIDs, whose structures have 
been resolved by X-ray crystallography.4,6,7 
In order to gain a further insight on the nature of drug-
receptor interactions, the salts of an arylpropionic acid and 
arginine have been synthesised in the present work, to 
approach the situation in drug-COX complexes, and its 
behaviour studied by photophysical techniques. Among the 
NSAIDs, naproxen (NPX) has been selected because its 
photophysical properties are well described in the 
literature.6 Thus, the possibilities of the first NPX singlet 
excited state to be used as reporter for the interaction of the 
drug with Arg have been explored. At this point it is worth 
mentioning that the antiinflammatory activity of NPX is 
mainly associated with the (S)-isomer.8 For this reason, it 
appeared interesting to compare the photophysical 
behaviour of the known (S)-NPX/(S)-Arg salt9 with that of 
its (R)/(S) isomer, that has not been previously described. 
To enhance the drug-amino acid interaction, the 
measurements have been performed on solid samples; the 
results have been discussed in connection with the X-ray 
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2. Results and discussion 
 The preparation of (S)-NPX/(S)-Arg and (R)-NPX/(S)-Arg 
(Scheme 1) was achieved by mixing equimolar amounts of 
(S)- or (R)- naproxen with (S)-arginine in deionized water. 








Scheme 1. Structural formulae of (S)-NPX/(S)-Arg and (R)-
NPX/(S)-Arg 
 The structural assignment was based on 1H-NMR, 13C-
NMR, IR, and X-ray chrystallography. 
2.1.  Fluorescence studies. 
 Fluorescence spectra of (S)-NPX/(S)-Arg and (R)-
NPX/(S)-Arg were first performed in solution (water and 
methanol), under nitrogen. For comparison, parallel 
experiments were carried out for the sodium salt of (S)-
naproxen ((S)-NPX/Na) under the same conditions. In all 
cases, the absorbance was 0.2 at the excitation wavelength 
(265 nm). The shape and position of the emission bands 
(centered at 350 nm), together with the fluorescence 
lifetimes of the two NPX-Arg salts (Table 1, entries 1, 2, 4 
and 5) matched with those of the NPX sodium salt (Table 
1, entries 3, 6). These results can be attributed to the fact 
that the interaction occurring between the two counterions 
of the salt in solution is relatively weak due to solvation.  
 In order to enhance the drug-amino acid interaction, the 
fluorescence spectra of (S)-NPX/(S)-Arg and (R)-NPX/(S)-
Arg were recorded in the solid state. In the former, the 
emission band displayed a maximum at 355 nm, very 
similar to the value obtained for solid (S)-NPX/Na; by 
contrast, (R)-NPX/(S)-Arg emitted at markedly longer 
wavelength (375 nm). The spectra of both salts are shown 
in Figure 1. Concerning the fluorescence lifetimes 
(measured at the emission maxima), a significant difference 
was found in the behaviour of the two diastereomers: while 
the (S,S)- salt had a τF value of 5.4 ns (Table 1, entry 7) 
very close to that of (S)-NPX/Na (5.8 ns, Table 1, entry 10) 
the (R,S)- isomer exhibited a much shorter τF (1.1 ns, Table 
1, entry 8). Thus, a significant stereodifferentiation was 
observed for the decay process, indicating a much more 
efficient deactivation of the NPX singlet in (R)-NPX/(S)-
Arg than in (S)-NPX/(S)-Arg. To rule out the possibility 
that this observation could be attributable to the presence of 
impurities in (R)-NPX/(S)-Arg, the salt (S)-NPX/(R)-Arg 
(with inverted configuration in both stereocenters) was 
prepared, and its emission spectra were measured in the 
solid state (see Table 1, entry 9 and Figure 1). As expected 
for two enantiomers, their photophysical properties were 
identical, confirming that their anomalous behaviour was 
not an artefact. Moreover, the fluorescence spectra 
measured for equimolar  mixtures of (R)-NPX and (S)-Arg  
or (S)-NPX and (S)-Arg  were identical to each other (in 
position and lifetime); they closely matched  the spectrum 
of (S)-NPX/Na. Thus, the obseved differences between the 
photophysical behaviour of the diastereomeric Arg salts in 
the solid state must be attributed to specific interactions 



















Figure 1. Fluorescence spectra of (S)-NPX/Na (□) , (S)-
NPX/(S)-Arg (■) , (R)-NPX/(S)-Arg, (●) and (S)-NPX/(R)-


































Table 1. Fluorescence lifetimes of (S)-NPX/(S)-Arg, (R)-
NPX/(S)-Arg, (S)-NPX/(R)-Arg and (S)-NPX/Na salts under 
different conditions. 
Entry Compound Conditions τF (ns) 
1 (S)-NPX/(S)-Arg H2O 9.2 
2 (R)-NPX/(S)-Arg H2O 9.1 
3 (S)-NPX/Na H2O 9.0 
4 (S)-NPX/(S)-Arg CH3OH 11.5 
5 (R)-NPX/(S)-Arg CH3OH 11.4 
6 (S)-NPX/Na CH3OH 11.4 
7 (S)-NPX/(S)-Arg solid 5.4 
8 (R)-NPX/(S)-Arg solid 1.1 
9 (S)-NPX/(R)-Arg solid 1.1 
10 (S)-NPX/Na solid 5.8 
 





























2.2. X-Ray structures. 
In order to ascertain whether the differences found in the 
fluorescence spectra in the solid state can be attributed to a 
different spatial arrangement of the counterpartners in the 
ionic network, single crystals of (S)-NPX/(S)-Arg and (R)-
NPX/(S)-Arg were obtained, and their structures were 
resolved by X-ray chrystallography (see unit cells in 


















The results showed that both salts crystallise in different 
spatial groups (trigonal and monoclinic, see table 2). 
Table 2. Chrystallographic data for (S)-NPX/(S)-Arg and (R)-
NPX/(S)-Arg 
 (S)-NPX/(S)-Arg (R)-NPX/(S)-Arg 
Empirical formula C40 H56 N8 O10 C20 H28 N4 O5 
Crystal system Monoclinic Trigonal 
Space group C 2 P 32 2 1 
Unit cell dimensions  a = 14.662(5) Å     a = 9.145(5) Å       
 b = 9.225(5) Å     b = 9.145(5) Å       
 c = 17.129(5) Å     c = 43.307(5) Å      
 α= 90.000(5)° α= 90.000(5)° 
 β= 113.865(5)° β= 90.000(5)° 







A closer look at the crystal structures revealed that the main 
feature with potential photophysical implications was the 
NPX to NPX interaction, due to the relative spatial 
arrangement of different units of this chromophore in the 
network. Thus, in the case of (R)-NPX/(S)-Arg (Figure 3) 
all the NPX moieties are parallel to each other and close 
enough as to produce excimer emission, while in the case 
of (S)-NPX/(S)-Arg (Figure 2) the observed non-parallel 
arrangement prevents an efficient π interaction between 
different naphthalene rings. In principle, exciplex formation 
between NPX and Arg was unexpected, as this type of 
interaction is associated with a certain degree of charge 
transfer that requires the presence of free amino groups as 
donors. Obviously, this is not possible in the NPX/Arg 
salts, where only ammonium ions are present. 
 
2.3. Excimer emission in a model dyad. 
As stated above, the new emission of (R)-NPX/(S)-Arg and 
(S)-NPX/(R)-Arg at longer wavelength can be assigned to a 
NPX excimer. In order to check this hypothesis, the 
fluorescence of solutions containing increasing amounts of 
NPX (from 4·10-5 M to 0.1 M) were measured. However, 
this was not enough as to generate the excimer, and the 
shape and the position of the spectral band (λmax = 355 nm) 
indicated that only the monomer was emitting . To force a 
stronger interaction, a bichromophoric dyad containing two 
covalently bound NPX-related subunits10 (Scheme 2) was 
prepared and spectroscopically characterised, and its 







Scheme 2. Structural formula of the model dyad. 
 
The fluorescence behaviour of the dyad in acetonitrile was 
compared with that of NPX in the same solvent; the 
normalised spectra are shown in Figure 4. In both cases, the 
emission maxima appear at λ = 355 nm; however, the 
shape of the bands is different at longer wavelengths, 
indicating that a new species is also emitting in the dyad. 
The difference between the above normalised spectra 
allows to obtain the fluorescence spectrum of the new 
species (Figure 4 insert), which can be attributed to the 
NPX-like excimer. Taking into account the different nature 
of the medium (solution vs. crystalline state) it is 










Figure 3. Unit cell for (R)-NPX/(S)-Arg 
O
O
H3CO OCH3  
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reasonably similar to the traces shown in Figure 1 for (R)-












Three diastereomeric salts of naproxen with arginine have 
been prepared, and their fluorescence spectra have been 
recorded in solution and in the solid state. Their emission 
properties in solution did not show significant differences, 
however the (R)-NPX/(S)-Arg and (S)-NPX/(R)-Arg solid 
salts displayed red-shifted fluorescence and a τF  value 
shorter than those of (S)-NPX/(S)-Arg and (R)-NPX/Na. 
This stereodifferentiation is explained based on the X-ray 
crystal structures and attributed to formation of NPX 
excimers emitting at longer wavelengths. Such excimer 
emission has been also observed in the fluorescence 
spectrum of a model NPX dyad in solution. 
4. Experimental section 
4.1. General 
Isolation and purification were done by recrystallysation. 
UV spectra were recorded in water or acetonitrile; λmax  
(nm) and log ε values (in parentheses) are given for each 
absorption band. IR spectra were obtained with a FTIR 
instrument; νmax (cm-1) is given for all the absorption bands. 
1H NMR and 13C NMR spectra were measured in D2O or 
CDCl3 with a 300-MHz instrument; chemical shifts are 
reported in δ(ppm) values. Mass spectra were determined 
under electron impact; the ratios m/z and the relative 
intensities (%) are indicated for the significant peaks.  
 
4.2. Synthesis of the substrates.  
To a solution of 173 mg (1 mmol) of S-arginine in 
deionised water (10 mL), 230 mg (1 mol) of S- or R- 
naproxen were added as a solid. The mixture was 
maintained under stirring for 30 min, the solvent was 
removed under vacuum and the crude solid was 
recrystallised from a 1:1 mixture of methanol and 
acetonitrile. The reaction was nearly quantitative. The 
crystals obtained following this procedure were suitable for 
X-ray characterisation. Crystallographic data (excluding 
structure factors) for the structures of (S)-NPX/(S)-Arg and 
(R)-NPX/(S)-Arg have been deposited with the Cambridge 
Crystallographic Data Centre as supplementary publication 
numbers CCDC 269482 and CCDC269481, respectively. 
 
4.3. Fluorescence measurements. 
Emission spectra were recorded on a spectrofluorimeter 
system, provided with a monochromator in the wavelength 
range 200-900 nm. For the experiments in solution, the 
samples were placed into 10 x 10 mm2 Suprasil quartz cells 
with a septum cap. The samples were purged with nitrogen 
for at least 15 min before the measurements The 
absorbance of the samples at the excitation wavelength was 
kept at 0.2. In the solid state, 2 x 10 mm2 Suprasil quartz 
cells were used. Excitation and emission slits were 
maintained unchanged during the emission experiments. 
For time resolved fluorescence decay measurements, the 
conventional single photon counting technique was used. 
 
4.4. Spectral data of the compounds. 
(S)-Arginine, mono[(S)-6-methoxy-α-methyl-2-
naphthalene acetate] ((S)-NPX/(S)-Arg). White crystals, 
m. p.189-202 ºC with decomposition. UV 230 (4.83), 262 
(3.72), 272 (3.71), 318 (3.14), 330 (3.22); FTIR 3552, 
3481, 3413, 3236, 1637, 1618, 1387, 1122, 621, 476; 1H 
NMR 7.73-7.67 (d+d , J = 8.4 Hz, 2H, 4,8-ArH), 7.62 (brs, 
1H, 1-ArH), 7.35 (dd, J1 = 8.4 Hz, J2 = 1.8 Hz, 1H, 3-ArH), 
7.22 (brs, 1H, 5-ArH), 7.08 (dd, 1H, J1 = 9.6 Hz, J1 = 2.7 
Hz, 7-ArH), 3.81 (s, 3H, OCH3), 3.68-3.59 (q+t, 2H, 
CHCH3, CHNH3), 3.06 (t, J = 6.2 Hz, 2H, CH2NH), 1.75 
(m, 2H, CH2CHNH3), 1.53 (m, 2H, NHCH2CH2), 1.35 (d, J 
= 7.2 Hz, 3H, CHCH3); 13C NMR: 183.7 (CH3CHCOO-), 
174.1 (NH2CHCOO-), 156.3 (6-C), 138.6 (2-C), 132.7 (4a-
C), 129.1-126.6 (8-CH, 8a-C, 4-CH, 9-CH), 125.0 (2-C), 
118.0 (7-CH), 105.9 (5-CH), 55.0 (OCH3), 54.0 (CHNH2), 
48.2 (CHCH3), 40.1 (CH2NH), 27.2 (CH2CH2CH), 23.5 
(CH2CH2CH), 18.0 (CHCH3). 
(S)-Arginine, mono[(R)-6-methoxy-α-methyl-2-
naphthalene acetate] ((R)-NPX/(S)-Arg). White crystals, 
m.p. 188-201 ºC with decomposition. 230 (4.83), 262 
(3.71), 272 (3.71), 318 (3.14), 330 (3.22); FTIR 3552, 
3481, 3413, 3236, 1637, 1618, 1387, 1118, 619, 471; 1H 
NMR 7.70-7.65 (d+d , J = 9 Hz, 2H, 4,8-ArH), 7.59 (brs, 
1H, 1-ArH), 7.31 (dd, J1 = 8.7 Hz, J2 = 1.8 Hz, 1H, 3-ArH), 
7.20 (brs, 1H, 5-ArH), 7.05 (d, 1H, J1 = 9.0, J2 = 2.4 Hz, 7-
ArH), 3.78 (s, 3H, OCH3), 3.65-3.57 (q+t, 2H, CHCH3, 
CHNH2), 3.06 (t, J = 6.9, 2H, CH2NH), 1.73 (m, 2H, 
Figure 4. Normalised fluorescence spectra of (S)-NPX (□), 
and the model dyad (●) in acetonitrile (λexc = 266 nm). Insert: 
fluorescence spectrum of the excimer obtained by difference 
between the normalised spectra of S-NPX and that of the 
model dyad. 
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CH2CHNH2), 1.50 (m, 2H, NHCH2CH2), 1.31 (d, 3H, J = 
7.2 Hz, CHCH3); ); 13C NMR: 183.7 (CH3CHCOO-), 174.1 
(NH2CHCOO-), 156.3 (6-C), 138.6 (2-C), 132.7 (4a-C), 
129.1-126.6 (8-CH, 8a-C, 4-CH, 9-CH), 125.0 (2-CH), 
118.0 (7-CH), 105.9 (5-CH), 55.0 (-OCH3), 54.0 (-
CHNH2), 48.2 (-CHCH3), 40.1 (CH2NH), 27.2 
(CH2CH2CH), 23.5 (CH2CH2CH), 18.0 (CHCH3). 
 
(R)-Arginine, mono[(S)-6-methoxy-α-methyl-2-naphta-
leneacetate] ((S)-NPX/(R)-Arg). White crystals, m.p.188-
202 ºC with decomposition. 230 (4.83), 262 (3.71), 272 
(3.71), 318 (3.14), 330 (3.22.); FTIR 3552, 3481, 3413, 
3236, 1637, 1618, 1387, 1122, 621, 476; 1H NMR 7.76-
7.71 (d+d , J = 8.4, 2H, 4,8-ArH), 7.66 (brs, 1H, 1-ArH), 
7.40 (dd, J1 = 8.4 Hz, J2 = 1.8 Hz, 1H, 3-ArH), 7.26 (brs, 
1H, 5-ArH), 7.11 (dd, 1H, J1 = 9 Hz, J2 = 2.3 Hz, 7-ArH), 
3.84 (s, 3H, OCH3), 3.72-3.63 (q+t, 2H, CHCH3, CHNH2), 
3.14 (t, 2H, J = 6.9, CH2NH), 1.80 (m, 2H, CH2CHNH2), 
1.55 (m, 2H, NHCH2CH2), 1.38 (d, 3H, J = 6.9 Hz, 
CHCH3); 13C NMR: 183.6 (CH3CHCOO-), 174.1 
(NH2CHCOO-), 156.3 (6-CO), 138.6 (2-C), 132.7 (4a-C), 
129.1-126.5 (8-CH, 8a-C, 4-CH, 9-CH), 125.0 (2-CH), 
118.0 (7-CH), 105.9 (5-CH), 55.0 (-OCH3), 54.0 (-
CHNH2), 48.2 (-CHCH3), 40.1 (CH2NH), 27.2 
(CH2CH2CH), 23.5 (CH2CH2CH), 18.0 (CHCH3). 
2-(2-methoxynaphthalen-6-yl)ethyl-2-(2-
methoxynaphthalen-6-yl) acetate. White crystals; UV 230 
(4.92), 262 (4.10), 272 (4.12), 318 (3.60), 330 (3.70); FTIR 
3551, 3478, 3412, 3236, 1637, 1617, 1265, 1133, 619, 481; 
1H NMR 7.64-7.48 (m, 6H, 1,4,8-ArH, and 1’,4’,8’-ArH), 
7.32-7.20 (dd+dd, J1 = 8.7 Hz, J2 = 2.1 Hz and J1 = 8.4 Hz, 
J2 = 1.8, 1H, 3-ArH and 3’-ArH), 7.14-7.08 (m, 4H, 5,7-
ArH and , 5’,7’-ArH), 4.39 (t, 2H, J = 6.9, CH2O), 3.93 and 
3.92 (s+s, 6H, OCH3), 3.72 (s, 2H, CH2CO), 3.04 (t, J = 
6.9 Hz, 2H, CH2CH2O); 13C NMR: 172.0 (CH2COO), 
157.9, 158.0 (6-C and 6’-C), 133.1-105.9 (aromatic C and 
CH), 65.6 (CH2COO), 55.6 (OCH3), 41.8 (CH2CO), 35.3 
(CH2CH2O); MS 400.30 (M+, 4%), 216.30 (9%), 185.3 
(16%), 184.29 (100%), 172.2 (10%), 171.20 (41%), 141.20 
(10%), 128.00 (23%), 115.20 (7%), 79.20 (60%). 
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